Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

MODERNA cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Only 23 countries use climate data for health surveillance, says head of WMO, adding more collaboration needed ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...